Pila Pharma has activated the clinical site that will conduct the first part of PP-CT04, the company’s twelve-week trial of its oral TRPV1 antagonist XEN-D0501 in obesity. The site was given permission to start enrolling participants in the initial safety cohort of eight and screened 6 participants on its first day.
Read the full article at biostock.se:
https://biostock.se/en/2026/10/obesity-trial-gets-underway-for-pila-pharma/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se